These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18852722)

  • 21. The once and future role of cytoreductive nephrectomy.
    Neill MG; Jewett MA
    Urol Oncol; 2008; 26(4):346-52. PubMed ID: 18367110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
    Wood CG; Margulis V
    Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study.
    Walther MM; Lyne JC; Libutti SK; Linehan WM
    Urology; 1999 Mar; 53(3):496-501. PubMed ID: 10096373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.
    Kirollos M
    BJU Int; 2008 Apr; 101(7):906; author reply 906-7. PubMed ID: 18321323
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: Capitanio et al.: Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. (Urology 2008;72:1090-1095).
    Chung SD; Chu SH; Tsai CC
    Urology; 2009 Mar; 73(3):682-3; author reply 683-4. PubMed ID: 19248907
    [No Abstract]   [Full Text] [Related]  

  • 27. Node positive renal cell cancer. Who can be helped?
    Messing EM
    Eur Urol; 2007 Jun; 51(6):1477-8. PubMed ID: 17240037
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.
    Crispen PL; Blute ML
    Curr Urol Rep; 2012 Feb; 13(1):38-46. PubMed ID: 22105577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of renal cell carcinoma.
    Pittman K; Selby P
    Crit Rev Oncol Hematol; 1994 Jun; 16(3):181-200. PubMed ID: 7521169
    [No Abstract]   [Full Text] [Related]  

  • 30. [Carcinoma of the Bellini collecting duct in paediatric patients: a case report and review of the literature].
    Gurrera A; Amico P; Di Cataldo A; Vasquez E; Magro G
    Pathologica; 2007 Oct; 99(5):301-5. PubMed ID: 18354951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8.
    Karakiewicz P; Perrotte P; Trinh QD; Patard JJ
    Eur Urol; 2007 Jun; 51(6):1478-80. PubMed ID: 17275988
    [No Abstract]   [Full Text] [Related]  

  • 33. Interferons in renal-cell carcinoma: status and prospects.
    De Mulder PH; Debruyne FM; Beniers AJ
    Prog Clin Biol Res; 1990; 348():49-59. PubMed ID: 1696737
    [No Abstract]   [Full Text] [Related]  

  • 34. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconciling the use of cytoreductive nephrectomy in the targeted therapy era.
    Culp SH
    Eur Urol; 2014 Oct; 66(4):711-2. PubMed ID: 25001889
    [No Abstract]   [Full Text] [Related]  

  • 36. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
    Vaishampayan UN
    Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of interferon-alpha-resistant renal cell carcinoma responding to interleukin-2 therapy].
    Kobori G; Yamada H; Higashi Y
    Hinyokika Kiyo; 2008 Oct; 54(10):657-9. PubMed ID: 19048930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.
    Russo P; O'Brien MF
    Urol Clin North Am; 2008 Nov; 35(4):679-86; viii. PubMed ID: 18992621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of renal surgery in the era of targeted therapy: the urologist's perspective.
    Battaglia M; Lucarelli G
    Urologia; 2015; 82(3):137-8. PubMed ID: 25704789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of metastatic renal cell carcinoma: current trends.
    Mohammed A; Shergill I; Little B
    Expert Rev Mol Diagn; 2009 Jan; 9(1):75-83. PubMed ID: 19099350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.